Nat Clin Pract Gastroenterol Hepatol. 2009;6(5):267-278. A thorough history and assessment of allergic diseases is a vital part of the evaluation of a patient with suspected EoE because of the ...

The 3 main treatments for EoE are medication, dietary therapy, or mechanical dilation of the esophagus. Patients should be evaluated individually to address their most problematic complaints first, ...

Researchers at Children's Hospital of Philadelphia (CHOP) identified a potential new therapeutic target for eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.

In the US, veterans with atopic diseases were more likely to develop eosinophilic esophagitis (EoE) than those without, with food allergies showing the strongest association. Overall, 26% (288,193) ...

PHILADELPHIA (WPVI) -- Allergic reactions come in all varieties. One can even trigger a digestive disease which makes it hard to swallow. It's known as EOE - Eosinophilic Esophagitis. For more than 30 ...

Please provide your email address to receive an email when new articles are posted on . The researchers used data from patients aged 1 to 18 years in the TriNetX Collaborative Network. Early diagnosis ...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).

Researchers at Children's Hospital of Philadelphia (CHOP) identified a potential new therapeutic target for eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.

Philadelphia, August 15, 2025 – Researchers from Children’s Hospital of Philadelphia (CHOP) and Children’s Hospital Colorado have found that better control of chronic eosinophilic esophagitis ...

Please provide your email address to receive an email when new articles are posted on . Patients with food allergies were 15.8 times more likely to develop eosinophilic esophagitis. The prevalence of ...

Worm-inspired biotech Holoclara has had a busy year. After announcing a $16 million series A round in June, the Pasadena, California, company has now dosed the first patient in a phase 1 trial of its ...

Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, ...